摘要
背景:Thymoquinone(TQ)是一种生物活性植物成分,由黑种(Nigella sativa)(黑种子)获得。它在预防癌症方面具有潜力。 目的:以前的研究表明,TQ可以调节负责癌症进展的信号通路,从而提高临床使用的抗癌药物的功效和改善安全性。 方法:TQ作用于细胞周期,通过靶向各种蛋白质(细胞周期蛋白D1,细胞周期蛋白E和p27)抑制从G1向S期的进展。它还表现出组蛋白去乙酰化酶(HDAC)抑制作用,靶向p21和Maspin,并诱导促凋亡基因Bax和下调抗凋亡基因Bcl-2。据报道,乳腺癌(BC)是妇女最常见的恶性肿瘤之一。结果:尽管研究和进步,它仍然是女性癌症相关死亡的最常见原因之一。 BC的分子筛选的最新进展导致鉴定三阴性乳腺癌(TNBC)的临床挑战性状况。 TNBC的特征是缺乏可靶向的受体,雌激素受体(ER),孕激素受体(PR)和人表皮生长因子受体2(HER2)的表达。其特征还在于磷酸酶和张力蛋白同系物(PTEN)表达的减少或缺失,所述肿瘤抑制基因具有调节细胞凋亡,细胞周期和转移的多种功能。 结论:由于已有报道TQ能够上调血管内皮生长因子(VEGF),EGF和PTEN表达等多种生长因子,因此本文综述了TQ对这类乳腺癌治疗干预的靶向潜能。
关键词: Thymoquinone,黑种子,HDAC,乳腺癌,TNBC,凋亡,VEGF。
图形摘要
Current Drug Targets
Title:Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
Volume: 19 Issue: 1
关键词: Thymoquinone,黑种子,HDAC,乳腺癌,TNBC,凋亡,VEGF。
摘要: Background: Thymoquinone (TQ) is a bioactive phytoconstituent obtained from Nigella sativa (black seeds). It has promising potential in cancer prevention.
Objective: Previous studies have shown that TQ can modulate signaling pathways responsible for cancer progression, thus enhancing the efficacy and improving the safety profile of clinically used anticancer drugs.
Method: TQ acts on cell cycle and inhibits progression from G1 to S phase by targeting various proteins (cyclin D1, cyclin E, and p27). It also exhibits histone deacetylase (HDAC) inhibitory effects, targets p21 and Maspin, and induces pro-apoptotic gene, Bax and downregulates anti-apoptotic gene Bcl-2. Breast cancer (BC) is reported as one of the most common malignancies in women.
Results: Despite the research and advancement, it remains one of the most common causes of cancer related deaths among women. Recent advancements in molecular screening of BC led to the identification of clinically challenging condition of triple negative breast cancer (TNBC). TNBC is characterized by the absence of targetable receptors viz. estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expressions. It is also characterized by reduced or absence of phosphatase and tensin homolog (PTEN) expression, a tumor suppressor gene having diverse functions including regulation of apoptosis, cell cycle, and metastasis.
Conclusion: Since TQ has been reported to up-regulate several growth factors such as vascular endothelial growth factor (VEGF), EGF and PTEN expression, the present review article discusses the targeting potential of TQ for therapeutic intervention against such types of breast cancer.
Export Options
About this article
Cite this article as:
Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer, Current Drug Targets 2018; 19 (1) . https://dx.doi.org/10.2174/1389450118666170612095959
DOI https://dx.doi.org/10.2174/1389450118666170612095959 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot topic: Natural Antioxidants and their Derivatives:Biology and Clinical Application (Guest Editors: Thea Magrone, Yoshio Kumazawa & Emilio Jirillo)]
Current Topics in Medicinal Chemistry Naturally Occurring Chitosan and Chitosan Derivatives: A Review
Current Drug Therapy Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews Effects of Motivational Interview on Awareness, Attitude, and Practice of Breast Self-examination in High-risk Women: A Clinical Trial Study
Current Women`s Health Reviews NGF and BDNF Alterations by Prenatal Alcohol Exposure
Current Neuropharmacology Preparation, Characterization, and In Vitro Release of Vinorelbine Tartrate (VLBT)- Loaded Folate-conjugated Recombination Human Serum Albumin (rHSA) Nanoparticles with Different Degree of Cross-linking
Current Nanoscience Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents
Current Pharmaceutical Design Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research Stem Cells in Brain Tumorigenesis and their Impact on Therapy
Current Stem Cell Research & Therapy Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry TGF-Beta Signaling Manipulation as Potential Therapy for IBD
Current Drug Targets Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry